Cemiplimab & Fianlimab - 2

DRUG3 trials

Sponsors

Regeneron Pharmaceuticals Inc.

Conditions

Fallopian Tube CancerMelanomaOvarian CancerPrimary Peritoneal CancerResectable Non-small Cell Lung Cancer

Phase 1

A PHASE 1/2 STUDY OF REGN5668 (MUC16 × CD28, A COSTIMULATORY BISPECIFIC ANTIBODY) ADMINISTERED IN COMBINATION WITH OTHER AGENTS IN MUC16+ MALIGNANCIES

RecruitingCTIS2022-501904-83-00

Regeneron Pharmaceuticals Inc.Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2023-09-11Target: 208Updated: 2025-12-03

Phase 2

A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared with Anti-PD1 Alone in Patients with Resectable Stage III and IV Melanoma

RecruitingCTIS2022-502825-17-00

Regeneron Pharmaceuticals Inc.Melanoma

Start: 2024-10-07Target: 254Updated: 2025-10-27

A Phase 2 Peri-Operative Trial of Fianlimab and Cemiplimab in Combination With Chemotherapy Versus Cemiplimab in Combination With Chemotherapy in Patients With Resectable Early Stage (Stage II to IIIB [N2]) NSCLC

Active, not recruitingCTIS2023-505172-29-00

Regeneron Pharmaceuticals Inc.Resectable Non-small Cell Lung Cancer

Start: 2025-04-24Target: 103Updated: 2025-08-29